DMD data to inform Santhera's choice under vamorolone option deal

Santhera and ReveraGen revealed Tuesday that glucocorticoid vamorolone showed improvement in timed function tests, the primary outcome for clinical efficacy, in a Phase IIa extension study in boys ages 4-7 with Duchenne muscular dystrophy.

Santhera Pharmaceuticals Holding AG (SIX:SANN) holds an option to license the program, which would complement

Read the full 494 word article

User Sign In